Wende Hutton
General Partner at Canaan Partners
Menlo Park, California
Writes $250K – $20M checks · typically $10M
About
Wende Hutton creates spinouts from big pharma by licensing shelved drugs with strong clinical data, assembling seasoned management, and using pharma relationships to drive acquisition-ready exits (Labrys→Teva, up to $825M).
Invests in
BiotechConsumerDeep TechDigital HealthEnterprise SoftwareFemTechFintechHardwareMedical Devices
Deals · 11
Qlaris BioBoard seat
via Canaan Partners · filed Jun 2026 · $3.9M raise
OncoResponseBoard seat
via Canaan Partners · filed May 2025
AlcheraBoard seat
via Canaan Partners · filed Nov 2021
HyalexBoard seat
via Canaan Partners · filed Jul 2021 · $34.9M raise
Antiva BiosciencesBoard seat
via Canaan Partners · filed Jul 2018 · $15M raise
Revision OpticsBoard seat
via Canaan Partners · filed Nov 2016 · $45M raise
Chrono TherapeuticsBoard seat
via Canaan Partners · filed Sep 2016 · $47.6M raise
Minimally Invasive DevicesBoard seat
via Canaan Partners · filed Nov 2015 · $14.1M raise
Butterfly HealthBoard seat
via Canaan Partners · filed May 2015 · $3.1M raise
Theraclone SciencesBoard seat
via Canaan Partners · filed May 2015 · $4.4M raise
Transcend Medical IncBoard seat
via Canaan Partners · filed Jan 2015 · $29.3M raise
Attribution from SEC filings, press coverage, and firm rosters.